

DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

April 21, 2021
MO HealthNet

[Join Webex Meeting](#)

Meeting number (access code): 177 549 2307

Join from a video system or application

Dial [1775492307@stateofmo.webex.com](tel:1775492307)

You can also dial 173.243.2.68 and enter your meeting number.

Tap to join from a mobile device (attendees only)

[+1-650-479-3207](tel:+16504793207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore
	Old Business	
10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
	New Business	
10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Agentsiv. Prior Authorization	Josh Moore
11:00 – 11:45	Clinical and Fiscal Edits <u>Existing Criteria</u> <ul style="list-style-type: none">i. Acne or Rosacea, Select Topical Agentsii. Givlaariiii. Megestroliv. Sickle Cell Diseasev. Systemic Antifungalsvi. Zulresso <u>New Criteria or Revision of Existing Criteria</u> <ul style="list-style-type: none">i. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulatorsii. Clobazam Agentsiii. Fabry Diseaseiv. Nocturnal Polyuriav. Opioids, Single Agents Short Actingvi. Oxlumovii. Spravato	Josh Moore

11:45 – 1:00

Preferred Drug List (PDL)

Josh Moore

Existing Criteria

- i. Actinic Keratosis Agents, Topical
- ii. Antifungals, Oral
- iii. Antihistamines, Intranasal
- iv. Antihistamines/Decongestant Combinations, Second Generation
- v. Antivirals, Oral
- vi. Antivirals, Topical
- vii. Benzoyl Peroxide/Antibiotic Combinations
- viii. Beta Adrenergic Agents, Long Acting
- ix. Beta Adrenergic Agents, Nebulized
- x. Cough/Cold Preparations
- xi. Fluoroquinolones, Ophthalmic
- xii. Mast Cell Stabilizers, Ophthalmic
- xiii. NSAIDs, Ophthalmic
- xiv. Pancreatic Enzymes
- xv. Psoriasis Agents, Oral
- xvi. Psoriasis Agents, Topical
- xvii. Retinoids, Topical
- xviii. Ulcerative Colitis Agents, Rectal

New Criteria or Revision of Existing Criteria

- i. Androgenic Agents
- ii. Antibiotics, Inhaled
- iii. Antifungals, Topical
- iv. Antihistamines, Ophthalmic
- v. Antiparasitics, Topical
- vi. Atopic Dermatitis Agents, Immunomodulators
- vii. Beta Adrenergic Agents, Short Acting
- viii. COPD Agents
- ix. Corticosteroids, Inhaled
- x. Corticosteroids, Intranasal
- xi. Corticosteroids, Ophthalmic Soft
- xii. Corticosteroids, Topical
- xiii. Epinephrine Agents, Self-Injectable
- xiv. Fluoroquinolones, Otic
- xv. Glaucoma Agents
- xvi. Hepatitis C Agents PDL Edit
- xvii. Hereditary Angioedema (HAE) Agents
- xviii. Leukotriene Receptor Modifiers
- xix. Respiratory Monoclonal Antibodies
- xx. Ulcerative Colitis, Oral

1:00 – 1:15

LUNCH

1:15 – 1:30

Program Utilization Information – Conduent Update

Jennifer Colozza

- i. Call Center Statistics
- ii. CyberAccess User Statistics
- iii. New Drug Statistics
- iv. “Top 25” Drugs by Cost/Claims

1:30 – 1:50

Other Business

- i. Sedative Hypnotic PDL Edit Changes Impact Report

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly.

NEXT MEETING: July 21, 2021

Meeting via Webex unless
otherwise specified